Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells-Reference-Cited by-同舟云学术

Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells

Published:2013-09-17 Issue:9 Volume:8 Page:e74415
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Auner Holger W.,Moody Anne Marie,Ward Theresa H.,Kraus Marianne,Milan Enrico,May Philippa,Chaidos Aristeidis,Driessen Christoph,Cenci Simone,Dazzi Francesco,Rahemtulla Amin,Apperley Jane F.,Karadimitris Anastasios,Dillon Niall

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference57 articles.

1. DangER: protein ovERload. Targeting protein degradation to treat myeloma;LI Aronson;Haematologica,2012

2. The mammalian unfolded protein response;M Schröder;Annu Rev Biochem,2005

3. One step at a time: endoplasmic reticulum-associated degradation;SS Vembar;Nat Rev Mol Cell Biol,2008

4. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress;I Tabas;Nat Cell Biol,2011

5. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition;G Bianchi;Blood,2009

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncogenic Mutant p53 Sensitizes Non-Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress-Dependent Induction of Mitochondrial Apoptosis;2024-02-25

2. Evaluation of the NRF1-proteasome axis as a therapeutic target in breast cancer;Scientific Reports;2023-09-22

3. Dual RNase activity of IRE1 as a target for anticancer therapies;Journal of Cell Communication and Signaling;2023-09-18

4. Inhibition of VCP modulates NF-κB signaling pathway to suppress multiple myeloma cell proliferation and osteoclast differentiation;Aging;2023-08-21

5. Preclinical Overview of Drugs Affecting Protein Turnover in Multiple Myeloma;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15